| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Venlafaxine | Effexor XR | 4.9 Overdose | Hypoglycaemia | Oct, 2024 |
| larotrectinib | Vitrakvi | 4.4 Special warnings and precautions for use | Hepatotoxicity | Nov,2024 |
| Pegvisomant | Somavert | 4.8 Undesirable effects | Sinusitis and infection | Oct, 2024 |
| Pantoprazole | Pantozol | 4.8 Undesirable effects | Rhabdomyolysis | Oct, 2024 |
| Aalirocumab | Praluent | 4.8 Undesirable effects | Added safety information in pediatrics | Sep, 2024 |
| Palbociclib | Ibrance | "4.5. Interactions with other medicinal products 4.8, Undesirable effects" | "Interaction with statins Blood creatinine increased and Erythema multiforme" | Sep, 2024 |